CICC has released a research report stating that it has kept its net profit forecasts for ANGELALIGN (06699) at $32 million for 2026 and $37 million for 2027. The firm maintains an "Outperform" rating but, considering the company's ongoing development momentum both domestically and internationally, it has raised the DCF-based target price by 22.4% to HK$104.0, implying a 30.2% upside from the current share price.
In the first half of the year, the number of cases increased by 40.2% year-on-year. On July 31, the company announced preliminary results for the first half of 2026: total revenue was approximately $229.0 to $231.0 million, up 41.9% to 43.1% year-on-year; net profit was approximately $24.0 to $25.4 million, up 69.0% to 78.9% year-on-year; and the total number of invisible orthodontic cases was approximately 316,600, a 40.2% year-on-year increase. The number of cases slightly exceeded market expectations, primarily due to the company's ongoing sales progress both domestically and internationally. Net profit also slightly exceeded expectations, mainly due to improved economies of scale.
Strengthening competitive advantages in the domestic market. According to the company's announcement, in the first half of 2026, the number of cases in the Chinese mainland market grew by approximately 36.8% to about 148,600. CICC believes this slightly exceeded market expectations, primarily because, in China's lower-tier cities, doctors are increasingly valuing professional reputation and patient experience, leading them to turn to professional products and services with stable efficacy, such as those from ANGELALIGN. The firm believes the company is well-positioned to continue actively seizing development opportunities in China's lower-tier markets.
Significant results from overseas professional brand investment. According to the company's announcement, in the first half of 2026, the number of cases in global markets (excluding Chinese mainland) grew by 43.3% to approximately 168,000. After several years of continuously building a global direct sales network, local customer service systems, and clinical support platforms, CICC believes the company's global operational system is becoming increasingly mature. According to the company's announcement, it will adhere to a development model that directly serves end-user dentists, continuously strengthening local clinical support, customer service, and doctor education systems in various countries, and gradually exiting OEM and commercial channel businesses that have low stickiness and lack pricing power.
Shifting towards invisible orthodontic systems with stable clinical efficacy. CICC believes that the rapid and sustained growth in the number of cases in the company's global markets is mainly due to the continuous enhancement of the company's professional brand influence and doctor recognition, with the customer Net Promoter Score (NPS) remaining high. Furthermore, according to the company's announcement, by leveraging an open management culture and a multinational talent team, it has integrated the strengths of multiple countries to achieve deep collaboration, thereby accelerating the pace of innovation in medical products, medical software, and medical services.
Risk factors: risks of research and development failure, risks of a deteriorating competitive landscape, and overseas business risks.
Comments